DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Information source: MSDx, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Relapsing Remitting Multiple Sclerosis

Intervention: MSDX Complex-1 Biomarker test (Other)

Phase: N/A

Status: Recruiting

Sponsored by: MSDx, Inc.

Official(s) and/or principal investigator(s):
Jeannette Wendt, MD, Principal Investigator, Affiliation: Northwest NeuroSpecialists, PLLC

Overall contact:
Marie Wesselhoft, Email: mwesselhoft@msdx.co


The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.

Clinical Details

Official title: A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Change in MSDX Complex-1 between baseline and 6-month visit

Secondary outcome: Gadolinium MRI and MSDX Complex-1 level


Minimum age: 45 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Diagnosis of clinically definite relapsing remitting MS (RRMS) 2. Age 45 years and older 3. Willing and able to provide written informed consent 4. Patient has high disease activity. 5. Patient is about to begin Natalizumab (Tysabri) therapy. Exclusion Criteria: 1. Any clinically significant disease other than MS that is likely to interfere with the evaluation of CDMS 2. Known infectious or hematological disease. 3. Unwilling or unable to comply with the requirements of this protocol 4. Subject can not have a gadolinium enhanced MRI

Locations and Contacts

Marie Wesselhoft, Email: mwesselhoft@msdx.co

Northwest NeuroSpecialists, PLLC, Tucson, Arizona 85741, United States; Recruiting
Jeanette Wendt, MD, Phone: 520-742-7890
Jeanette Wendt, MD, Principal Investigator
Additional Information

Starting date: January 2012
Last updated: February 29, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017